Skip to main content

Table 1 Descriptive characteristics of the study patients (N = 76)

From: Clinical outcome of patients with differentiated thyroid cancer and raised antithyroglobulin antibody levels: a retrospective study

Variables

Mean

Median

Percentile (Q1, Q3)

Age (years) at diagnosis

35.71 ± 14.01

34

25, 45

Time between Surgery and RIT

3.64 ± 1.65

3.0

3, 4.8

RIT (mCi)

66.05 ± 41.12

60.0

30,100

Tg Baselinea

5.98 ± 16.78

0.27

20, 2.80

Tg after RITa

0.66 ± 1.24

0.20

0.20, 0.79

TgAb (baseline)b

713.29 ± 1073.6

166.50

70, 675.3

TgAb after RITb

420.23 ± 830.56

103.0

10,339.5

TgAb (% change, Baseline-early follow up)

−34.29 ± 68.62

−47.57

−78.97, −11.96

TgAb (final)b

450.42 ± 1185.20

53.0

10, 245.5

TgAb (% change, Baseline-last follow up)

−52.62 ± 53.16

−73.48

−86.90, −33.40

Follow up Duration (months)

58.74 ± 26.26

55

42.30, 71.8

  1. RIT High dose Radiodiodine Therapy, Tg Serum Thyroglobulin, TgAb Serum Antithyroglobulin antibody
  2. aTg level expressed in ng/dl
  3. bTgAb level expressed in IU/ml